Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
Konstantinidis
Lazaros
L
Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Mantel
Irmela
I
Zografos
Leonidas
L
Ambresin
Aude
A
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D056833:Central Serous Chorioretinopathy / Q000150:complications*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D005451:Fluorescein Angiography; D005456:Fluorescent Dyes; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005456:Fluorescent Dyes; D007208:Indocyanine Green; D000069579:Ranibizumab